Modulation of lipid metabolism for protein production

Patent metadata

Field	Value
Publication number	US-10655111-B2
Application number	US-201715585570-A
Country	US
Kind code	B2
Filing date	May 3, 2017
Priority date	May 3, 2016
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.

First claim

What is claimed is:

1. A cell comprising:
a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM), wherein the first LMM comprises a sterol regulatory element-binding transcription factor 1 (SREBF1) or a functional fragment or isoform thereof; and
an exogenous nucleic acid encoding a recombinant polypeptide,
wherein the first exogenous nucleic acid is integrated into the chromosomal genome of the cell; and
wherein the cell is a CHO-derived cell.

2. The cell of claim 1 , wherein the cell is selected from the group consisting of CHO-K1, CHOK1SV, Potelligent CHOK1SV (FUT8-KO), CHO GS-KO, Exceed (CHOK1SV GS-KO), CHO-S, CHO DG44, CHO DXB11, and CHOZN.

3. The cell of claim 1 , wherein the first LMM modulates the expression of the recombinant polypeptide.

4. The cell of claim 3 , wherein the first LMM alters the expression of a component involved in a lipid metabolism pathway.

5. The cell of claim 1 , further comprising a second exogenous nucleic acid encoding a second LMM, wherein the second exogenous nucleic acid encoding a second LMM is integrated into the chromosomal genome of the cell.

6. The cell of claim 5 , wherein the second LMM is selected from a transcription regulator that mediates the expression of a lipid metabolism gene product selected from SREBF2 (sterol regulatory element-binding transcription factor 2), PRMT5, FAS (fatty acid synthase), ACC (acetyl-coA carboxylase), ACL (ATP citrate lyase), DGAT (diglyceride acyltransferase), GPAT (glycerol 3-phosphate acyltransferase), LPL (lipoprotein lipase), AGPAT (1-actyl-sn-glycerol-3-phosphate O-acyltransferase), AGNPR (acyl/alkylglycerone-phosphate reductase), CCT (phosphocholine cytidyltransferase), CDS (phosphatidate cytidylyltransferase), CEPT (diacylglycerol choline/ethanolaminephosphotransferase), CERT (ceramide transfer protein), CGT (N-acylsphingosine galactosyltransferase), CPT (diacylglycerol cholinephosphotransferase), CLS (cardiolipin synthase), CRD (ceramidase), GNPAT (glycerone-phosphate O-acyltransferase), KDSR (3-ketosphinganine reductase), LCS (polypeptide N-acetylgalactosaminyltransferase), PAP (phosphatidic acid phosphatase), PEMT (phosphatidylethanolamine N-methyltransferase), PGP (phosphatidylglycerophosphatase), PGS (CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase), PIS (CDP-diacylglycerol-inositol 3-phosphatidyltransferase), PSD (phosphatidylserine decarboxylase), PSS1 (phosphatidylserine synthase 1), PSS2 (phosphatidylserine synthase 2), SGMS (ceramide choline phosphotransferase), SNAT (sphingosine N-acyltransferase), SPK (sphinganine kinase), SPP (sphingosine-1-phosphate phosphatase), SPT (serine Co-palmitoyltransferase), PED (plasmanylethanolamine desaturase), S1P (site-1 protease), S2P (site-2 protease), SCAP (SREBF cleavage-activating protein), INSIG1 (insulin induced gene 1), INSIG2 (insulin induced gene 2), HMG CoA reductase (2-hydroxy-3-methylgulatryl-CoA reductase), a PPAR receptor, or a functional fragment or analog of any of the same.

7. The cell of claim 5 , wherein the second LMM is selected from: SCD1 (stearoyl CoA desaturase-1), SCD2 (stearoyl CoA desaturase-2), SCD3 (stearoyl CoA desaturase-3), SCD4 (stearoyl CoA desaturase-4), SCD5 (Steoryl CoA desaturase-5).

Assignees

• Lonza Ag

Inventors

• Budge James
• Smales Christopher Mark
• Knight Tanya Jeane
• Young Robert

Classifications

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K14/4702

  Regulators; Modulating activity · CPC title

• C12N9/0083

  Miscellaneous (1.14.99) · CPC title

• C12N9/0097 Primary

  acting on reduced flavodoxin as donor (1.19) · CPC title

• C12Y114/19001

  Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase · CPC title